This competitive renewal application for a Specialized Program of Research Excellence (SPORE) in Cervical Cancer at the Johns Hopkins University School of Medicine, University of Alabama at Birmingham and University of Colorado brings together a highly interactive, multidisciplinary, and inter-institutional program of translational research in cervical cancer. The SPORE includes four integrated projects spanning the fields of prevention and treatment of cervical cancer. Project I: L1 Capsomeres as a Next Generation Preventive HPV Vaccine, led by Robert Garcea, M.D., Richard Roden, Ph.D., and Warner Huh, M.D. Project II: Development of a Pan-Oncogenic HPV Preventive Vaccine, led by Richard Roden, Ph.D., and Warner Huh, M.D. Project III;A phase I clinical trial to assess the immunogenicity, safety, tolerability and efficacy of HPV DNA-Vaccinia prime booster vaccination with locally applied TLR agonists in patients with HPV-16+ cervical intraepithelial neoplasia 3 (CIN3), led by Cornelia Trimble, M.D., Drew Pardoll, M.D., Ph.D. and T.-C. Wu, M.D., Ph.D. Project IV: A phase I clinical trial to assess the safety and immunogenicity of repeated, cluster particle-mediated epidermal delivery (PMED) of the DNA vaccine, pNGVL4a-CRT-E7(detox), in patients with operable Stage IB1 cervical cancer associated with HPV-16, led by Ronald Alvarez, M.D., Connie Trimble, M.D. and T.-C. Wu, M.D., Ph.D. These four projects are supported by four Cores that provide critical and supportive infrastructure essential to efficient and effective translational research. The Administration/ Communication Core (Core A) led by T. C. Wu, M.D., Ph.D. and Edward Partridge, M.D, the Biostatistics/ Data Management Core (Core B) led by Mei-Cheng Wang, Ph.D., and Sreelatha Meleth, Ph.D., the Tissue /Pathology Core (Core C) led by Brigitte Ronnett, M.D. and Lawrence Lamb, Ph.D. and the Immunology Core (Core D) led by Raphael Viscidi, M.D. and Chien-Fu Hung, Ph.D. The SPORE also includes a Developmental Research Program for rapid funding of novel research ideas and a Career Development Program to facilitate career development of individuals with interest in translational cervical cancer research.

Public Health Relevance

The intent of our program is to reduce the incidence of cervical cancer and to improve the outcome in patients with HPV associated cervical cancer and their precursor lesions by developing innovative vaccination strategies for the prevention and treatment of cervical cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Lin, Alison J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Sinno, A K; Li, X; Thompson, R E et al. (2017) Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care. Gynecol Oncol 145:493-499
Stewart, Katherine Ikard; Fader, Amanda N (2017) New Developments in Minimally Invasive Gynecologic Oncology Surgery. Clin Obstet Gynecol 60:330-348
Jiang, Rosie T; Wang, Joshua W; Peng, Shiwen et al. (2017) Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection. J Virol 91:
Yoo, Wonsuk; Kim, Sangmi; Huh, Warner K et al. (2017) Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One 12:e0172548
Moukarzel, Lea A; Angarita, Ana M; VandenBussche, Christopher et al. (2017) Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. J Low Genit Tract Dis 21:91-96
Huh, Warner K; Guido, Richard (2017) Transitioning from HPV 101 to HPV 202. Am J Obstet Gynecol 216:206-207
Yang, Pei-Ming; Chou, Chia-Jung; Tseng, Ssu-Hsueh et al. (2017) Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. Oncotarget 8:46145-46162
Fader, Amanda N (2017) Minimally Invasive Techniques for Treating Gynecologic Malignancies. J Natl Compr Canc Netw 15:730-732
Mehta, Ambar; Xu, Tim; Hutfless, Susan et al. (2017) Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications. Am J Obstet Gynecol 216:497.e1-497.e10
Yang, Andrew; Farmer, Emily; Lin, John et al. (2017) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res 231:148-165

Showing the most recent 10 out of 273 publications